A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy

Summary

The investigators propose a preventive strategy that may reduce the risk of placental vascular disease and its negative consequences for both the fetus (e.g., poor fetal growth or stillbirth)and mother (e.g., the hypertensive disorders of pregnancy), and which, in turn, should reduce the need for indicated preterm delivery. This strategy is a multicenter, randomized double-blind, placebo-controlled clinical trial (RCT) comparing magnesium citrate supplementation with placebo, each starting at 12 to 20 weeks gestation and continued until delivery. Magnesium citrate is a safe and inexpensive compound that is easily absorbed by the intestinal tract. The results of this RCT may be especially relevant in low and middle income countries that have high rates of prematurity, and limited resources for acute newborn and maternal care.

Timeline

Start

2014-03

Primary completion

2015-08

Completion

2015-12

Publications

• de Araujo CAL, Ray JG, Figueiroa JN, Alves JG. BRAzil magnesium (BRAMAG) trial: a double-masked randomized clinical trial of oral magnesium supplementation in pregnancy. BMC Pregnancy Childbirth. 2020 Apr 21;20(1):234. doi: 10.1186/s12884-020-02935-7.
• de Araujo CAL, de Sousa Oliveira L, de Gusmao IMB, Guimaraes A, Ribeiro M, Alves JGB. Magnesium supplementation and preeclampsia in low-income pregnant women - a randomized double-blind clinical trial. BMC Pregnancy Childbirth. 2020 Apr 9;20(1):208. doi: 10.1186/s12884-020-02877-0.
• Alves JG, de Araujo CA, Pontes IE, Guimaraes AC, Ray JG. The BRAzil MAGnesium (BRAMAG) trial: a randomized clinical trial of oral magnesium supplementation in pregnancy for the prevention of preterm birth and perinatal and maternal morbidity. BMC Pregnancy Childbirth. 2014 Jul 8;14:222. doi: 10.1186/1471-2393-14-222.

Drugs

Indications